Biosign appoints new Chief Financial Officer and schedules Investor Conference Call
/NOT FOR DISTRIBUTION IN THE UNITED STATES OR THROUGH UNITED STATES WIRE SERVICES/
TORONTO, Jan. 6, 2014 /CNW/ - Biosign Technologies Inc. (TSXV: BIO) ("Biosign" or the "Company") is pleased to announce the appointment of Mr. Mario Laflamme, CA, CPA as Chief Financial Officer, to replace Mr. William Randolph (Randy) Polley, CA who will remain with the Company as a senior business development executive.
Mr. Laflamme will oversee Biosign's finance and accounting functions, utilizing extensive financial management and corporate development experience gained through working with rapidly growing firms in the technology sector in both the United States and Canada. He most recently served as CFO for LED Roadway Lighting, a Halifax, Nova Scotia based outdoor lighting technology company; as Managing Director of Mass Tech Partners, a Massachusetts based business and financial management firm; and as President & CFO of Univisions Crimson Group, a corporate Audio/Video services firm formed by the merger of Univisions and Crimson Tech, and sold to York Telecom. Notably, Mr. Laflamme was Vice President, Finance and Vice President, Operations for The Learning Company, (formerly SoftKey Software), a Canadian company that grew through acquisitions to over $800 million in revenue and was later acquired by Mattel Inc.
The Company wishes to thank Mr. Polley for his service as CFO. He has helped guide Biosign through our intense restructuring period, and his dedication, skill and professionalism are greatly appreciated. We are pleased that he has agreed to continue working with us as a key executive in the areas of business development and sales.
Biosign's CEO Mr. Robert Kaul stated, "We are very pleased to welcome Mr. Laflamme to Biosign as our new CFO. He brings us specific experience working with fast growing companies in both Canada and the United States, which we will need as we move forward with our previously articulated plan to grow by acquisition in 2014 and beyond. Furthermore, as Biosign increasingly commits to doing business in Atlantic Canada, Mr. Laflamme's location in Halifax will be a benefit as we engage more deeply with government and industry stakeholders in that region."
INVESTOR CONFERENCE CALL JANUARY 9, 2014
Biosign is pleased to announce an Investor Conference Call, scheduled for Thursday, January 9th, 2014 at 11:00 AM Eastern Daylight Time. During this call, Biosign CEO Robert Kaul will read a prepared statement commenting on recent news releases and providing additional discussion on the Company's business plan.
To participate in the call, please use the following login credentials:
Dial-In Number: Local: (718) 514-2085, Toll Free: 1-877-394-5901
No PIN number is required. Participants can dial Star 1 (*1) to ask a question during the call - a live operator will be moderating.
In particular, Mr. Kaul will comment on the following announcements:
- "Biosign licenses award-winning applepeak source code" November 18, 2013
- "Biosign repatriates exclusive rights for Middle East and Asia" November 25, 2013
- "Biosign and RJL Systems announce co-marketing agreement" December 23, 2013
- "Biosign invests in HR infrastructure company" December 24, 2013
- "Biosign announces $6.0 million software and services sale" December 27, 2013
- "Biosign acquires IBL Internet Business Logic Inc" December 31, 2013
Plus any additional releases issued prior to the date of the conference call.
Following the presentation, Mr. Kaul will answer a number of questions submitted from participants regarding the business of the Company. The conference call is open to any investor or stakeholder, including shareholders, broker-dealers and other securities professionals. The call will be recorded and available for review at http://biosign.com/investors.
To submit one or more questions to the CEO, please email your question to firstname.lastname@example.org with the words "Investor Question for Conference Call" in the subject line. Biosign management will endeavour to address as many questions as possible in the one-hour time period allocated to the call.
Biosign CEO Robert Kaul stated, "Biosign has recently made a number of material announcements related to our business plan. Management is pleased to be able to communicate with investors and other interested parties in order to place these announcements into greater context, and to address various stakeholder inquiries."
About Biosign Technologies Inc.
Biosign Technologies Inc. (TSXV: BIO) provides automated, software enabled health information solutions including the Pulsewave® Health Monitor and the Healthanywhere™ Patient monitoring / self-management platform. The Company's Pulsewave® Health Monitor solution enables pulse wave data collection for cardiovascular clinical decision support and self-care, while its Healthanywhere™ solution offers industry-leading remote patient monitoring and patient centred care management. The Company also offers a number of cardiovascular screening programs for consumers under its Heart Friendly™ brand, including Heart Friendly™ Practice, Heart Friendly™ Dentist, and Heart Friendly™ Fitness. For more information on Biosign, please visit www.biosign.com
This release contains forward-looking statements. Forward-looking statements, without limitation, may contain the words believes, expects, anticipates, estimates, intends, plans, or similar expressions. Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions and Biosign's actual results could differ materially from those anticipated. Forward looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. In the context of any forward-looking information please refer to risk factors detailed in, as well as other information contained in the company's filings with Canadian securities regulators (www.sedar.com).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Biosign Technologies Inc.For further information:
Biosign Contact Information:
Chief Executive Officer
Phone: (416) 218-9800 ext. 201